TMP-SMX vs Placebo for Uncomplicated Skin Abscess
Talan DA et al.. “TrimethoprimโSulfamethoxazole versus Placebo for Uncomplicated Skin Abscess”.ย NEJM. 2016. 374(9):823-832.
PubMedย Full textย PDF
Clinical Question
In settings with MRSA, doesย Trimethoprim-sulfamethoxazoleย treatment afterย Incision and drainageย of anย abscessย result in a greater cure rate?
Conclusion
Trimethoprimโsulfamethoxazole treatment resulted in a higher cure rate among patients with a drained cutaneousย abscessย than placebo forย abscessย that are successfully drained.
Major Points
Methicillin-resistant Staphylococcus aureus (MRSA) is a well known cause of many abscesses in the ED being the most common cause of purulent skin and soft-tissue infections.[1][2][3]ย Treatment for cutaneous abscesses has beenย incision and drainageย with antibiotics generally reserved for those that also had associated cellulitis. This multicenter, double-blind, randomized Controlled Trial of 5 US EDs with >1200 patients challenges the traditional dogma of no antibiotics for simple small uncomplicated abscesses that can be drained. For abscess of median size, 2.5 x 2.0 x 1.5cm that underwent I&D and co-administration of 5 days ofย TMP/SMX, cure rates were 80.5% vs 73.6% with placebo and I&D.[4]
-
ย Maligner D et al. The prevalence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in skin abscesses presenting to the pediatric emergency department. N C Med J. 2008 Sep-Oct;69(5):351-4.
-
Pickett A et al. Changing incidence of methicillin-resistant staphylococcus aureus skin abscesses in a pediatric emergency department. Pediatr Emerg Care. 2009 Dec;25(12):831-4.
-
Bradley W. Frazee et al. High Prevalence of Methicillin-Resistant Staphylococcus aureus in Emergency Department Skin and Soft Tissue Infectionsย http://dx.doi.org/10.1016/j.annemergmed.2004.10.011
-
Talan DA et al.. “TrimethoprimโSulfamethoxazole versus Placebo for Uncomplicated Skin Abscess”. NEJM. 2016. 374(9):823-832. [EBQ:TMP-SMX vs Placebo for Uncomplicated Skin Abscess|Bactrim and I&D NEJM]]